Last updated on September 2017

A Randomized Multicenter Phase III Trial Comparing Enzalutamide vs. a Combination of Ra223 and Enzalutamide in Asymptomatic or Mildly Symptomatic Castration Resistant Prostate Cancer Patients Metastatic to Bone.


Brief description of study

A Randomized Multicenter Phase III Trial Comparing Enzalutamide vs. a Combination of Ra223 and Enzalutamide in Asymptomatic or Mildly Symptomatic Castration Resistant Prostate Cancer Patients Metastatic to Bone.

Detailed Study Description

The objective of this randomized phase III open label trial is to assess if upfront combination of enzalutamide and Ra223 improves radiological progression-free survival compared to enzalutamide single agent in asymptomatic or mildly symptomatic castration resistant prostate cancer patients metastatic to bone.

For Study Locations, Click Here

Clinical Study Identifier: TX153168

Find a site near you

Start Over

Research Center

Located in: Additional Locations, XX Belgium
  Connect »

Research Center

Located in: Additional Locations, XX Italy
  Connect »

Research Center

Located in: Additional Locations, XX Poland
  Connect »

Research Center

Located in: Additional Locations, XX Spain
  Connect »

Research Center

Located in: Additional Locations, XX United Kingdom
  Connect »

Research Center

Located in: Additional Locations, XX Denmark
  Connect »

Research Center

Located In: Additional Locations, XX Switzerland
  Connect »